

[Amodiaquine - sulfadoxine + pyrimethamine](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.2. Antimalarial medicines > Medicines for chemoprevention](#)

ATC codes: [P01BA06](#) [P01BD51](#)

EMLc

Indication

Malaria ICD11 code: [1F4Z](#)

INN

Amodiaquine + sulfadoxine + pyrimethamine

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc) ; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc)

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Children (1 month - 12 years)

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Amodiaquine - sulfadoxine + pyrimethamine](#)

[DrugBank](#)

[Amodiaquine](#),

[Sulfadoxine](#),

[Pyrimethamine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strengths of co-packaged amodiaquine with sulfadoxine + pyrimethamine to the EMLc for seasonal malaria chemoprevention in children.